Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry.

Kaunisto J, Salomaa ER, Hodgson U, Kaarteenaho R, Kankaanranta H, Koli K, Vahlberg T, Myllärniemi M.

ERJ Open Res. 2019 Jul 8;5(3). pii: 00170-2018. doi: 10.1183/23120541.00170-2018. eCollection 2019 Jul.

2.

Age- and gender-specific incidence of new asthma diagnosis from childhood to late adulthood.

Honkamäki J, Hisinger-Mölkänen H, Ilmarinen P, Piirilä P, Tuomisto LE, Andersén H, Huhtala H, Sovijärvi A, Backman H, Lundbäck B, Rönmark E, Lehtimäki L, Kankaanranta H.

Respir Med. 2019 Jul - Aug;154:56-62. doi: 10.1016/j.rmed.2019.06.003. Epub 2019 Jun 8.

PMID:
31212122
3.

Cumulative effect of smoking on disease burden and multimorbidity in adult-onset asthma.

Tommola M, Ilmarinen P, Tuomisto LE, Lehtimäki L, Niemelä O, Nieminen P, Kankaanranta H.

Eur Respir J. 2019 May 2. pii: 1801580. doi: 10.1183/13993003.01580-2018. [Epub ahead of print] No abstract available.

PMID:
31048351
4.

YKL-40 and adult-onset asthma: Elevated levels in clusters with poorest outcome.

Ilmarinen P, Tuomisto LE, Niemelä O, Hämäläinen M, Moilanen E, Kankaanranta H.

J Allergy Clin Immunol Pract. 2019 Apr 4. pii: S2213-2198(19)30328-9. doi: 10.1016/j.jaip.2019.03.043. [Epub ahead of print] No abstract available.

5.

What Patients Can Tell Us About Their Asthma.

Kankaanranta H, Israel E.

J Allergy Clin Immunol Pract. 2019 Mar;7(3):906-907. doi: 10.1016/j.jaip.2018.11.031. No abstract available.

PMID:
30832895
6.

Transient Receptor Potential Ankyrin 1 Enhances Ovalbumin-Induced Acute Allergic Inflammation in Murine Models.

Moilanen LJ, Hämäläinen M, Ilmarinen P, Kankaanranta H, Nieminen RM, Moilanen E, Lehtimäki L.

Int Arch Allergy Immunol. 2019;178(3):238-247. doi: 10.1159/000494932. Epub 2019 Jan 30.

PMID:
30699406
7.

Immediate bronchodilator response in FEV1 as a diagnostic criterion for adult asthma.

Tuomisto LE, Ilmarinen P, Lehtimäki L, Tommola M, Kankaanranta H.

Eur Respir J. 2019 Feb 14;53(2). pii: 1800904. doi: 10.1183/13993003.00904-2018. Print 2019 Feb. Review.

PMID:
30464017
8.

Daily physical activity and lung function decline in adult-onset asthma: a 12-year follow-up study.

Loponen J, Ilmarinen P, Tuomisto LE, Niemelä O, Tommola M, Nieminen P, Lehtimäki L, Kankaanranta H.

Eur Clin Respir J. 2018 Oct 24;5(1):1533753. doi: 10.1080/20018525.2018.1533753. eCollection 2018.

9.

Prevalence of Patients Eligible for Anti-IL-5 Treatment in a Cohort of Adult-Onset Asthma.

Ilmarinen P, Tuomisto LE, Niemelä O, Kankaanranta H.

J Allergy Clin Immunol Pract. 2019 Jan;7(1):165-174.e4. doi: 10.1016/j.jaip.2018.05.032. Epub 2018 Jun 9.

10.

Inhaled corticosteroids and asthma control in adult-onset asthma: 12-year follow-up study.

Vähätalo I, Ilmarinen P, Tuomisto LE, Niemelä O, Kankaanranta H.

Respir Med. 2018 Apr;137:70-76. doi: 10.1016/j.rmed.2018.02.025. Epub 2018 Mar 2.

PMID:
29605216
11.

Nordic consensus statement on the systematic assessment and management of possible severe asthma in adults.

Porsbjerg C, Ulrik C, Skjold T, Backer V, Laerum B, Lehman S, Janson C, Sandstrøm T, Bjermer L, Dahlen B, Lundbäck B, Ludviksdottir D, Björnsdóttir U, Altraja A, Lehtimäki L, Kauppi P, Karjalainen J, Kankaanranta H.

Eur Clin Respir J. 2018 Mar 6;5(1):1440868. doi: 10.1080/20018525.2018.1440868. eCollection 2018. Review.

12.

Chronic obstructive pulmonary disease guidelines in Europe: a look into the future.

Miravitlles M, Roche N, Cardoso J, Halpin D, Aisanov Z, Kankaanranta H, Kobližek V, Śliwiński P, Bjermer L, Tamm M, Blasi F, Vogelmeier CF.

Respir Res. 2018 Jan 18;19(1):11. doi: 10.1186/s12931-018-0715-1. Review.

13.

Concern of underdiagnosing asthma-COPD overlap syndrome if age limit of 40 years for asthma is used.

Tommola M, Ilmarinen P, Tuomisto LE, Kankaanranta H.

Eur Respir J. 2017 Aug 3;50(2). pii: 1700871. doi: 10.1183/13993003.00871-2017. Print 2017 Aug. No abstract available.

14.

Comparison of feasibility and estimates of central and peripheral nitric oxide parameters by different mathematical models.

Karvonen T, Kankaanranta H, Saarelainen S, Moilanen E, Lehtimäki L.

J Breath Res. 2017 Sep 13;11(4):047102. doi: 10.1088/1752-7163/aa7cc0.

PMID:
28665296
15.

Glycoprotein YKL-40 Levels in Plasma Are Associated with Fibrotic Changes on HRCT in Asbestos-Exposed Subjects.

Väänänen T, Lehtimäki L, Vuolteenaho K, Hämäläinen M, Oksa P, Vierikko T, Järvenpää R, Uitti J, Kankaanranta H, Moilanen E.

Mediators Inflamm. 2017;2017:1797512. doi: 10.1155/2017/1797512. Epub 2017 May 14.

16.

Differences between asthma-COPD overlap syndrome and adult-onset asthma.

Tommola M, Ilmarinen P, Tuomisto LE, Lehtimäki L, Haanpää J, Niemelä O, Kankaanranta H.

Eur Respir J. 2017 May 1;49(5). pii: 1602383. doi: 10.1183/13993003.02383-2016. Print 2017 May.

17.

Cluster Analysis on Longitudinal Data of Patients with Adult-Onset Asthma.

Ilmarinen P, Tuomisto LE, Niemelä O, Tommola M, Haanpää J, Kankaanranta H.

J Allergy Clin Immunol Pract. 2017 Jul - Aug;5(4):967-978.e3. doi: 10.1016/j.jaip.2017.01.027. Epub 2017 Apr 25.

18.

The effect of smoking on lung function: a clinical study of adult-onset asthma.

Tommola M, Ilmarinen P, Tuomisto LE, Haanpää J, Kankaanranta T, Niemelä O, Kankaanranta H.

Eur Respir J. 2016 Nov;48(5):1298-1306. doi: 10.1183/13993003.00850-2016. Epub 2016 Sep 22.

19.

Age-specific incidence of new asthma diagnoses in Finland.

Kankaanranta H, Tuomisto LE, Ilmarinen P.

J Allergy Clin Immunol Pract. 2017 Jan - Feb;5(1):189-191.e3. doi: 10.1016/j.jaip.2016.08.015. Epub 2016 Oct 17. No abstract available.

PMID:
27765463
20.

Comorbidities and elevated IL-6 associate with negative outcome in adult-onset asthma.

Ilmarinen P, Tuomisto LE, Niemelä O, Danielsson J, Haanpää J, Kankaanranta T, Kankaanranta H.

Eur Respir J. 2016 Oct;48(4):1052-1062. doi: 10.1183/13993003.02198-2015. Epub 2016 Aug 18.

21.

A 12-year prognosis of adult-onset asthma: Seinäjoki Adult Asthma Study.

Tuomisto LE, Ilmarinen P, Niemelä O, Haanpää J, Kankaanranta T, Kankaanranta H.

Respir Med. 2016 Aug;117:223-9. doi: 10.1016/j.rmed.2016.06.017. Epub 2016 Jun 23.

22.

Emerging Comorbidities in Adult Asthma: Risks, Clinical Associations, and Mechanisms.

Kankaanranta H, Kauppi P, Tuomisto LE, Ilmarinen P.

Mediators Inflamm. 2016;2016:3690628. doi: 10.1155/2016/3690628. Epub 2016 Apr 26. Review.

23.

A review of national guidelines for management of COPD in Europe.

Miravitlles M, Vogelmeier C, Roche N, Halpin D, Cardoso J, Chuchalin AG, Kankaanranta H, Sandström T, Śliwiński P, Zatloukal J, Blasi F.

Eur Respir J. 2016 Feb;47(2):625-37. doi: 10.1183/13993003.01170-2015. Epub 2016 Jan 21. Review.

24.

Phenotypes, Risk Factors, and Mechanisms of Adult-Onset Asthma.

Ilmarinen P, Tuomisto LE, Kankaanranta H.

Mediators Inflamm. 2015;2015:514868. doi: 10.1155/2015/514868. Epub 2015 Oct 11. Review.

25.

Re-evaluation of diagnostic parameters is crucial for obtaining accurate data on idiopathic pulmonary fibrosis.

Kaunisto J, Kelloniemi K, Sutinen E, Hodgson U, Piilonen A, Kaarteenaho R, Mäkitaro R, Purokivi M, Lappi-Blanco E, Saarelainen S, Kankaanranta H, Mursu A, Kanervisto M, Salomaa ER, Myllärniemi M.

BMC Pulm Med. 2015 Aug 19;15:92. doi: 10.1186/s12890-015-0074-3.

26.

Seinäjoki Adult Asthma Study (SAAS): a protocol for a 12-year real-life follow-up study of new-onset asthma diagnosed at adult age and treated in primary and specialised care.

Kankaanranta H, Ilmarinen P, Kankaanranta T, Tuomisto LE.

NPJ Prim Care Respir Med. 2015 Jun 25;25:15042. doi: 10.1038/npjpcrm.2015.42. No abstract available.

27.

Prognosis of new-onset asthma diagnosed at adult age.

Tuomisto LE, Ilmarinen P, Kankaanranta H.

Respir Med. 2015 Aug;109(8):944-54. doi: 10.1016/j.rmed.2015.05.001. Epub 2015 May 21. Review.

28.

The polyamine spermine promotes survival and activation of human eosinophils.

Ilmarinen P, Moilanen E, Erjefält JS, Kankaanranta H.

J Allergy Clin Immunol. 2015 Aug;136(2):482-4.e11. doi: 10.1016/j.jaci.2014.12.1922. Epub 2015 Jan 30. No abstract available.

PMID:
25649081
29.

Diagnosis and pharmacotherapy of stable chronic obstructive pulmonary disease: the finnish guidelines.

Kankaanranta H, Harju T, Kilpeläinen M, Mazur W, Lehto JT, Katajisto M, Peisa T, Meinander T, Lehtimäki L.

Basic Clin Pharmacol Toxicol. 2015 Apr;116(4):291-307. doi: 10.1111/bcpt.12366. Epub 2015 Jan 22. Review.

30.

Regulation of spontaneous eosinophil apoptosis-a neglected area of importance.

Ilmarinen P, Moilanen E, Kankaanranta H.

J Cell Death. 2014 Feb 10;7:1-9. doi: 10.4137/JCD.S13588. eCollection 2014. Review.

31.

[Update on current care guideline: chronic obstructive pulmonary disease (COPD)].

Harju T, Kankaanranta H, Katajisto M, Kilpeläinen M, Lehtimäki L, Lehto J, Mazur W, Meinander T, Peisa T.

Duodecim. 2014;130(17):1774-6. Finnish.

PMID:
25272791
32.

Eosinophil intracellular signalling: apoptosis.

Ilmarinen P, Moilanen E, Kankaanranta H.

Methods Mol Biol. 2014;1178:71-80. doi: 10.1007/978-1-4939-1016-8_7.

PMID:
24986608
33.

Adipokines NUCB2/nesfatin-1 and visfatin as novel inflammatory factors in chronic obstructive pulmonary disease.

Leivo-Korpela S, Lehtimäki L, Hämälainen M, Vuolteenaho K, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E.

Mediators Inflamm. 2014;2014:232167. doi: 10.1155/2014/232167. Epub 2014 May 6.

34.

Mitochondria in the center of human eosinophil apoptosis and survival.

Ilmarinen P, Moilanen E, Kankaanranta H.

Int J Mol Sci. 2014 Mar 5;15(3):3952-69. doi: 10.3390/ijms15033952. Review.

35.

Tumour necrosis factor-α regulates human eosinophil apoptosis via ligation of TNF-receptor 1 and balance between NF-κB and AP-1.

Kankaanranta H, Ilmarinen P, Zhang X, Adcock IM, Lahti A, Barnes PJ, Giembycz MA, Lindsay MA, Moilanen E.

PLoS One. 2014 Feb 28;9(2):e90298. doi: 10.1371/journal.pone.0090298. eCollection 2014.

36.

Enhanced expression of neuropeptide S (NPS) receptor in eosinophils from severe asthmatics and subjects with total IgE above 100IU/ml.

Ilmarinen P, James A, Moilanen E, Pulkkinen V, Daham K, Saarelainen S, Laitinen T, Dahlén SE, Kere J, Dahlén B, Kankaanranta H.

Peptides. 2014 Jan;51:100-9. doi: 10.1016/j.peptides.2013.10.030. Epub 2013 Nov 13.

PMID:
24239856
37.

Eosinophil apoptosis as a therapeutic target in allergic asthma.

Ilmarinen P, Kankaanranta H.

Basic Clin Pharmacol Toxicol. 2014 Jan;114(1):109-17. doi: 10.1111/bcpt.12163. Epub 2013 Nov 13. Review.

38.

Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD.

Leivo-Korpela S, Lehtimäki L, Vuolteenaho K, Nieminen R, Kööbi L, Järvenpää R, Kankaanranta H, Saarelainen S, Moilanen E.

Respir Med. 2014 Jan;108(1):122-8. doi: 10.1016/j.rmed.2013.08.016. Epub 2013 Aug 30.

39.

Cost effectiveness of adding budesonide/formoterol to tiotropium in COPD in four Nordic countries.

Nielsen R, Kankaanranta H, Bjermer L, Lange P, Arnetorp S, Hedegaard M, Stenling A, Mittmann N.

Respir Med. 2013 Nov;107(11):1709-21. doi: 10.1016/j.rmed.2013.06.007. Epub 2013 Jul 13.

40.

Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1.

Korhonen R, Hömmö T, Keränen T, Laavola M, Hämäläinen M, Vuolteenaho K, Lehtimäki L, Kankaanranta H, Moilanen E.

Br J Pharmacol. 2013 Aug;169(7):1525-36. doi: 10.1111/bph.12189.

41.

[Update on current care guidelines: asthma].

Haahtela T, Lehtimäki L, Ahonen E, Harju T, Jartti T, Kankaanranta H, Korhonen K, Mäkelä M, Puurunen M, Sovijärvi A, Valovirta E, Venho KK.

Duodecim. 2013;129(9):994-5. Review. Finnish.

PMID:
23786112
43.

Effects of heparin and related drugs on neutrophil function.

Brown RA, Leung E, Kankaanranta H, Moilanen E, Page CP.

Pulm Pharmacol Ther. 2012 Apr;25(2):185-92. doi: 10.1016/j.pupt.2012.01.006. Epub 2012 Feb 4.

PMID:
22327105
44.

Dexamethasone and RU24858 Induce Survival and Growth Factor Receptor Bound Protein 2, Leukotriene B4 Receptor 1 and Annexin-1 Expression in Primary Human Neutrophils.

Janka-Junttila M, Hasala H, Adcock I, Moilanen E, Kankaanranta H.

J Cell Death. 2012 Jan 28;5:21-9. doi: 10.4137/JCD.S9097. eCollection 2012.

45.

[Pulmonary nocardiosis in a farmer].

Kupila N, Kankaanranta H, Sauni R.

Duodecim. 2011;127(21):2315-9. Finnish.

PMID:
22204147
46.

Adipokine resistin predicts anti-inflammatory effect of glucocorticoids in asthma.

Leivo-Korpela S, Lehtimäki L, Vuolteenaho K, Nieminen R, Kankaanranta H, Saarelainen S, Moilanen E.

J Inflamm (Lond). 2011 May 26;8:12. doi: 10.1186/1476-9255-8-12.

47.

Salbutamol delays human eosinophil apoptosis via a cAMP-dependent mechanism.

Kankaanranta H, Parkkonen J, Ilmarinen-Salo P, Giembycz MA, Moilanen E.

Pulm Pharmacol Ther. 2011 Aug;24(4):394-400. doi: 10.1016/j.pupt.2011.03.002. Epub 2011 Mar 15.

PMID:
21396479
48.

Nitric oxide induces apoptosis in GM-CSF-treated eosinophils via caspase-6-dependent lamin and DNA fragmentation.

Ilmarinen-Salo P, Moilanen E, Kankaanranta H.

Pulm Pharmacol Ther. 2010 Aug;23(4):365-71. doi: 10.1016/j.pupt.2010.04.001. Epub 2010 Apr 7.

PMID:
20380887
49.

Histone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils.

Kankaanranta H, Janka-Junttila M, Ilmarinen-Salo P, Ito K, Jalonen U, Ito M, Adcock IM, Moilanen E, Zhang X.

J Inflamm (Lond). 2010 Feb 4;7:9. doi: 10.1186/1476-9255-7-9.

50.

Pulmonary inflammation in asbestos-exposed subjects with borderline parenchymal changes on HRCT.

Lehtimäki L, Oksa P, Järvenpää R, Vierikko T, Nieminen R, Kankaanranta H, Uitti J, Moilanen E.

Respir Med. 2010 Jul;104(7):1042-9. doi: 10.1016/j.rmed.2010.01.019. Epub 2010 Feb 16.

Supplemental Content

Loading ...
Support Center